In the phase 1a/b TRAVERSE trial (NCT04696731), patients with advanced clear cell renal cell carcinoma (ccRCC) who had progressed after immune checkpoint inhibitors and VEGF-targeted treatments received a single infusion of ALLO-316 following lymphodepletion. Here, VEGFA is linked to clear cell renal carcinoma.